Cart
sales@molnova.com
Rimtuzalcap
CAS No. 2167246-24-2
Rimtuzalcap( CAD-1883 )
Catalog No. M28737 CAS No. 2167246-24-2
Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 5MG | 67 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 216 | In Stock |
|
| 50MG | 313 | In Stock |
|
| 100MG | 443 | In Stock |
|
| 200MG | 619 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRimtuzalcap
-
NoteResearch use only, not for human use.
-
Brief DescriptionRimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels).
-
DescriptionRimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA).(In Vitro):Rimtuzalcap (Compound 1) is a small molecule modulator of potassium ion channels showing great therapeutic potential for treating a variety of diseases characterized by dysfunction of potassium ion channels and dysfunction from other causes which influence these potassium channels.(In Vivo):Rimtuzalcap (CAD-1883) reduces the firing rate of Purkinje cells by approximately 40%, consistent with the anticipated therapeutic mechanism of positive allosteric modulation of SK channels. Sequential bath application of 1 or 3 μM CAD-1883 results in a partial reversal of the increased coefficient of variation of the interspike interval which is seen in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice.
-
In VitroRimtuzalcap (Compound 1) is a small molecule modulator of potassium ion channels showing great therapeutic potential for treating a variety of diseases characterized by dysfunction of potassium ion channels and dysfunction from other causes which influence these potassium channels.
-
In VivoRimtuzalcap (CAD-1883) reduces the firing rate of Purkinje cells by approximately 40%, consistent with the anticipated therapeutic mechanism of positive allosteric modulation of SK channels. Sequential bath application of 1 or 3 μM CAD-1883 results in a partial reversal of the increased coefficient of variation of the interspike interval which is seen in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice.
-
SynonymsCAD-1883
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
Recptorhuman glucagon receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2167246-24-2
-
Formula Weight378.428
-
Molecular FormulaC18H24F2N6O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (660.64 mM)
-
SMILESCc1ccn(n1)-c1nc(NC2CCC(F)(F)CC2)cc(n1)N1CCOCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.M A Cascieri, et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem. 1999 Mar 26;274(13):8694-7.
molnova catalog
related products
-
E-4031 dihydrochlori...
E-4031 is a class III antiarrhythmic agent that binds to Kv11.1 (hERG) and blocks the rapid delayed-rectifier K+ current (IKr).
-
Agitoxin 2
Potent Shaker K+ channel blocker (Ki = 0.64 nM). Also inhibits Kv1.3, Kv1.6 and Kv1.1 K+ channels (Ki values are 4, 37 and 44 pM respectively).
-
RU-TRAAK-2
RU-TRAAK-2 is a reversible inhibitor of TWIK-related arachidonic acid-stimulated K+ channel with no activity for non-K2P channels including Kv1.2, GIRK2, and Slo1.
